Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fabrazyme infusion rate escalation in Fabry disease
NCT06019728Phase 4Completed
- Sponsor
- Sanofi
- Start
- Nov 2023
- Primary completion
- Oct 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of agalsidase beta in Fabry disease (FD), sponsored by Sanofi. Started Nov 2023; status: completed.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT06019728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06019728.